Form D · Pharmaceuticals

NBO Pharma Inc.

Bedford, NY · CIK 0002103906

Offering snapshot reported Jan 22, 2026 · SEC filing

Reported sold: $7.64M
Investors reported: 93
Minimum accepted: $10K
First sale: Jun 12, 2025

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jan 22, 2026	Initial	$7,640,217	No comparison	93	SEC filing

Offering details

Securities: Equity, Option to acquire
Exemptions: 06c
Duration over one year: No
Business combination: No

Sales commissions: $947K
Finders' fees: $0
Form D file number: 021-570878

The total amount sold includes (i) $625,000 from conversion of SAFES and (ii) $7,015,217 from cash investment.

Issuer provided placement agent (i) 13% of gross proceeds received from qualifying investors (ii) a $35,000 non-accountable expense fee and (iii) a number of warrants equal to 15% of the total number of shares sold to qualifying investors in the offering.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Paulson Investment Company, LLC	5670

Source: Form D, filed Jan 22, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Colin Foster	Director
Robert Friedman	Director
Bard Geesaman	Director
Fredric David Price	Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

64 Quarry Lane
Bedford, NY, 10506
Phone: 914-645-1130